P-1574. Asymptomatic Bacteriuria Not a Predictor of Clinical Failure in Uncomplicated Urinary Tract Infections (uUTI): A Prospective Analysis of Women Treated for uUTI from the REASSURE Trial
Aronin S, Dunne M, Puttagunta S. P-1574. Asymptomatic Bacteriuria Not a Predictor of Clinical Failure in Uncomplicated Urinary Tract Infections (uUTI): A Prospective Analysis of Women Treated for uUTI from the REASSURE Trial. Open Forum Infectious Diseases 2025, 12: ofae631.1741. PMCID: PMC11776810, DOI: 10.1093/ofid/ofae631.1741.Peer-Reviewed Original ResearchPresence of asymptomatic bacteriuriaAsymptomatic bacteriuriaUncomplicated UTIClinical failureMMITT populationTOC visitClinical responseEfficacy endpointTreatment armsTreatment of uncomplicated UTIUncomplicated urinary tract infectionsPredictor of clinical failureTreatment of UTIUrinary tract infectionAdult womenAnalysis of womenCausative uropathogensDouble-dummyActive controlled trialUTI symptomsDouble-blindAsymptomatic patientsPrimary endpointTract infectionsEfficacy outcomesP-1107. Oral Sulopenem/probenecid for Uncomplicated Urinary Tract Infections (uUTI): Results from the REASSURE Trial
Puttagunta S, Aronin S, Gupta J, Das A, Gupta K, Dunne M. P-1107. Oral Sulopenem/probenecid for Uncomplicated Urinary Tract Infections (uUTI): Results from the REASSURE Trial. Open Forum Infectious Diseases 2025, 12: ofae631.1295. PMCID: PMC11777793, DOI: 10.1093/ofid/ofae631.1295.Peer-Reviewed Original ResearchUncomplicated urinary tract infectionsTreatment-emergent adverse eventsTreatment of uncomplicated urinary tract infectionsSusceptible to amoxicillin/clavulanateMMITT populationAdverse eventsFrequent treatment-emergent adverse eventsTreatment of multidrug-resistant infectionsBaseline urine cultureOral antibiotic optionsEmergent adverse eventsUrinary tract infectionMultidrug-resistant infectionsAdult womenTreatment of adult womenAmoxicillin/clavulanate groupDouble-dummyActive controlled trialAntibiotic optionsUrine cultureOral antibioticsResistant uropathogensDouble-blindStudy drugPrimary endpoint
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply